Morgan Stanley cuts Denali Therapeutics price target to $37 from $42
Morgan Stanley lowered its Denali Therapeutics price target to $37 a share from $42 while keeping its Overweight rating.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Morgan Stanley has reduced its price target on Denali Therapeutics shares to $37 from $42 a share. According to Dow Jones Newswires, citing Benzinga, the bank kept its Overweight rating on the company unchanged.
why it matters
Single-analyst target changes mainly matter to investors holding the company's own shares. For the broader market, adjustments like this are usually of little significance.
tags
instruments
sources
- Denali Therapeutics Price Target Cut to $37.00/Share From $42.00 by Morgan Stanley — Dow Jones Newswires, 13 November 2026 at 17:58 UTC
- Axsome Therapeutics Price Target Cut to $223.00/Share From $249.00 by Morgan Stanley — Dow Jones Newswires, 13 November 2026 at 18:05 UTC
- argenx Price Target Cut to $1130.00/Share From $1190.00 by Morgan Stanley — Dow Jones Newswires, 13 November 2026 at 18:03 UTC
- Genmab Price Target Cut to $56.00/Share From $57.00 by Morgan Stanley — Dow Jones Newswires, 13 November 2026 at 18:06 UTC
- Exelixis Price Target Cut to $57.00/Share From $60.00 by Morgan Stanley — Dow Jones Newswires, 13 November 2026 at 18:09 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗